ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sunderman FW, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sunderman FW, S.
Annals of Clinical and Laboratory Science, Vol 21, Issue 1, 70-81
Copyright © 1991 by Association of Clinical Scientists

Articles

Therapeutic properties of sodium diethyldithiocarbamate: its role as an inhibitor in the progression of AIDS

Sr Sunderman FW

The therapeutic history of sodium diethyldithiocarbamate (dithiocarb) is briefly reviewed. Dithiocarb was discovered serendipitously in our laboratory 35 years ago for the specific treatment of nickel carbonyl poisoning. Since that time, the therapeutic efficacy of dithiocarb has been reported for many disorders, including: nickel, cadmium, thallium, copper, and mercury poisonings, experimental nickel carcinogenesis, protection against radiation damage to bone marrow, treatment of candidiasis in experimental animals, hepatolenticular degeneration (Wilson's disease), systemic lupus erythematosis, and human immunodeficiency virus infection (HIV). It has been used as an antagonist to cisplatin and cyclophosphamide toxicities, and as an antidote to hepatotoxicity induced by chloroform, carbon tetrachloride, and halothane. Most recently, it has been observed that the progression of HIV-1 infection is inhibited by dithiocarb administered intravenously or orally to patients with acquired immunodeficiency syndrome (AIDS). Attention is directed to the interactions of divalent cations to viral infections and to metal chelators (e.g., dithiocarb) as potential antiviral agents.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Gupta, D. Young, and S. Sen
Inhibition of NF-{kappa}B induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H20 - H29.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
A. Nurmi, P. J. Lindsberg, M. Koistinaho, W. Zhang, E. Juettler, M.-L. Karjalainen-Lindsberg, F. Weih, N. Frank, M. Schwaninger, and J. Koistinaho
Nuclear Factor-{kappa}B Contributes to Infarction After Permanent Focal Ischemia
Stroke, April 1, 2004; 35(4): 987 - 991.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. R. Thomas, H. Salahifar, R. Mashima, N. H. Hunt, D. R. Richardson, and R. Stocker
Antioxidants Inhibit Indoleamine 2,3-Dioxygenase in IFN-{{gamma}}-Activated Human Macrophages: Posttranslational Regulation by Pyrrolidine Dithiocarbamate
J. Immunol., May 15, 2001; 166(10): 6332 - 6340.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Knobil, A. M. K. Choi, G. W. Weigand, and D. B. Jacoby
Role of oxidants in influenza virus-induced gene expression
Am J Physiol Lung Cell Mol Physiol, January 1, 1998; 274(1): L134 - L142.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. G. Bowie, P. N. Moynagh, and L. A. J. O'Neill
Lipid Peroxidation Is Involved in the Activation of NF-kappa B by Tumor Necrosis Factor but Not Interleukin-1 in the Human Endothelial Cell Line ECV304. LACK OF INVOLVEMENT OF H2O2 IN NF-kappa B ACTIVATION BY EITHER CYTOKINE IN BOTH PRIMARY AND TRANSFORMED ENDOTHELIAL CELLS
J. Biol. Chem., October 10, 1997; 272(41): 25941 - 25950.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the Association of Clinical Scientists.